Rosetta Genomics (ROSG) announced that the company has entered into a co-promotional commercial partnership with Precipio Diagnostics for the sales and marketing of Precipio’s oncology tests, which include bone marrow and peripheral blood testing for hematological malignancies, such as leukemias and lymphomas.
These products are being promoted by Rosetta in California, Connecticut, New Jersey, Oklahoma, Texas, Virginia and Washington, D.C., with an expectation to expand nationally over time.
Precipio Diagnostics is the only cancer diagnostics company to successfully combine the experience, knowledge and expertise of academic-level pathology from the Yale School of Medicine with commercial-level service.
Oncologists around the world benefit from direct access to the highest quality of diagnostic support, coupled with rapid and efficient service.
"Both Rosetta and Precipio have outstanding products that serve the same customers. Joining forces to offer these services through this partnership strengthens both companies’ value proposition, and improves the quality and level of services that our customers receive," said Ilan Danieli, Chief Executive Officer of Precipio Diagnostics.